BMRN Stock Analysis: Buy, Sell, or Hold?
BMRN - BioMarin Pharmaceuticals Inc
$66.70
-0.98 (-1.45%)
âŧ
5d:
-0.98%
30d:
+13.3%
90d:
+23.29%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When BMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BMRN is fairly priced but lacks strong directional signals. At 2.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BMRN is fairly priced but lacks strong directional signals. At 2.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$119.73
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$74.34
10.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMRN is currently trading at $66.70, which is considered slightly high relative to its 30-day fair value range of $58.75 to $66.81. The stock's valuation (Forward PE: 10.3) is in line with its historical norms (9.5). At these levels, the market is pricing in 2.9% annual earnings growth.
Technical Outlook: Technically, BMRN is in a strong uptrend. Immediate support is located at $63.37, while resistance sits at $70.98.
Market Sentiment: BMRN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $91.04 (+36.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BMRN is in a strong uptrend. Immediate support is located at $63.37, while resistance sits at $70.98.
Market Sentiment: BMRN scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $91.04 (+36.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$58.75 -
$66.81
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
46.2%
Protect Your Profits
Holding BMRN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 36.5% below Wall St target ($91.04)
- BULLISH: Expecting earnings turnaround to 2.9% growth with 19.9% revenue growth
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$58.75 -
$66.81
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$63.37
Resistance Level
$70.98
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.31
Wall Street Target
$91.04
(+36.5%)
Revenue Growth (YoY)
19.9%
Earnings Growth (YoY)
-81.3%
Profit Margin
2.1%
Valuation Premium vs History
+2.9% premium
PE vs Historical
10.3 vs 9.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.9%
(market-implied from PE analysis)
1-Year Target
$68.63
(+3%)
2-Year Target
$70.62
(+6%)
3-Year Target
$72.67
(+9%)
3-Yr Target (if PE normalizes)
(PE: 10â10)
PE COMPRESSION
$66.99
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 28.8%)
$277.55
(+316%)
Base:
(SPY PE: 10.3, Growth: 28.8%)
$142.52
(+114%)
Bear:
(PE: 8.8, Growth: 28.8%)
$121.14
(+82%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Forward PE: 13.99 | Forward EPS (Implied): $4.77
Bull Case
$80.54
(+21%)
Analyst growth 15.0%, PE expands to 14.7
Base Case
$66.70
(0%)
Market implied 0.0%, PE stable at 14.0
Bear Case
$51.03
(-24%)
Severe decline -15.0%, PE contracts to 12.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 24, 2026 6:59 AM ET
Data refreshes hourly during market hours. Next update: 7:59 AM
Data refreshes hourly during market hours. Next update: 7:59 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles Greg Guyer
SELL
16486 shares
2026-03-11
Gregory R Friberg
SELL
6326 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 35 SELL |
Advanced BMRN Option Strategies
Professional options setups generated by AI based on today's BMRN price and gamma walls.
